Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07286266 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

StatusRecruiting
PhasePhase 3
Started2026-06-18
View on ClinicalTrials.gov ↗
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer compared to standard treatments. The study also assesses whether Mo-Rez is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.

Amendment history 6 changes detected by DataLookout

2026-07-16
Primary completion moved earlier: 2030-08-21 → 2029-12-17
2026-07-16
Completion moved earlier: 2030-08-21 → 2029-12-17
2026-07-09
Recruitment opened
2026-07-09
Trial sites expanded: 0 → 5 locations
2026-05-28
Primary completion pushed: 2030-07-22 → 2030-08-21
2026-05-28
Completion pushed: 2030-07-22 → 2030-08-21
Trial Details
NCT Number NCT07286266
Lead Sponsor GlaxoSmithKline
Collaborators: GOG, ENGOT, APGOT
Conditions Ovarian Neoplasms
Enrollment 450 participants
Start Date 2026-06-18
Primary Completion 2029-12-17 (estimated)
Study Completion 2029-12-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-15